CSA (Coordination and Support Action)
Immune-Image has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
01/10/2019 - 30/09/2024 (5 years)VIEW PARTNERS >
1 Stichting VUMC
2 Eberhard Karls Universität Tübingen
3 University of Cambridge
4 Westfälische Wilhelms-Universität Münster
5 Vrije Universiteit Brussel
6 Vlaams Instituut voor Biotechnologie
7 Academisch Ziekenhuis Groningen/
8 University Medical Centre Groningen
9 Vall d’Hebron Institute of Oncology
10 Vall d’Hebron Institute of Research
11 Atomic Energy and Alternative Energies Commission
12 Antaros Medical AB
13 Stichting Lygature
14 ttopstart BV
15 Lawrencium Legal BV
16 European Cancer Patient Coalition
17 F. Hoffmann-La Roche AG
18 Bayer AG
19 Janssen Pharmaceutica NV
20 Novartis Pharma AG
21 Pfizer Ltd.
22 ImagineAb Inc.
23 Takeda Pharmaceutical International AG
Why it matters?
“Immunotherapy, a treatment that uses a person’s own immune system to fight cancer was science-fiction a few years ago, now it is reality. Although challenges linked to the therapy are still significant when it comes to accessibility or reimbursement schemes. We need to make sure that all EU citizens have appropriate information, equal access to the newest cancer treatment and that they can afford it.”
Antonella Cardone, ECPC Director
What ECPC does
ECPC supports communication and dissemination of the Immuno-Image project’s outcomes towards cancer patients and cancer organisations during the duration of the whole project. This involves conveying information about the trials to confirm safety and to evaluate the clinical potential of novel immunotracers to ECPC cancer patient community and other relevant European patient organisations. ECPC involves multiple patient organisations who would benefit from the project outcomes.